Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
British Journal of Haematology|February 13, 2003
Cell surface CD43 determination improves diagnostic precision in late B-cell diseasesGeorges Jung, Jean-Claude Eisenmann, Sylvie Thiébault, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|January 17, 2015
Secondary thrombotic microangiopathy in two patients with Philadelphia-positive hematological malignancies treated with imatinib mesylateMario Ojeda-Uribe, Sylvain Merieau, Marie Guillon, et al.
British Journal of Haematology|April 23, 2014
Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemiaEdouard Cornet, Cécile Tomowiak, Aline Tanguy-Schmidt, et al.
Blood Advances|July 17, 2020
Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE studyMarie-Helene Delfau-Larue, Marie-Laure Boulland, Asma Beldi-Ferchiou, et al.
Haematologica|March 15, 2015
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomideMichel Delforge, Leonard Minuk, Jean-Claude Eisenmann, et al.
Blood Cancer Journal|May 29, 2020
Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-upJerome Paillassa, Edouard Cornet, Stephanie Noel, et al.
Blood|October 5, 2018
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myelomaLaurent Garderet, Frederique Kuhnowski, Benoit Berge, et al.
British Journal of Haematology|November 9, 2019
Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC studyCatherine Thieblemont, Susannah Howlett, René-Olivier Casasnovas, et al.
Blood|March 23, 2016
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trialPhilippe Moreau, Cyrille Hulin, Margaret Macro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2019
Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I TrialXavier Leleu, Guillemette Fouquet, Valentine Richez, et al.
Pageof 2